Few adverse effects were reported for the orally administered drug CNV2197944 in both young and elderly patients, indicating that the drug has an “optimal profile for a chronic pain medication,” the company said.
Convergence is currently developing a Phase II trial for the drug.
Related Articles on Pain Management:
RS Medical to Launch Nimbus Radiofrequency Ablation Device
University of New England Researcher Receives $140K Grant to Study Cancer Pain
Memorial Hospital of Union County, Pain Management Group Open Pain Center
